1. Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 Infection. N Engl J Med. 364: 1943-54, 2011.
  2. DHHS: Guideline for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (October 25, 2018). (https://aidsinfo.nih.gov/guidelines/)
  3. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral Drugs for treatment and Prevention of HIV infection in Adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 320: 379-96, 2018.
  4. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update) (https://www.bhiva.org/HIV-1-treatment-guidelines).
  5. European AIDS clinical society (EACS) guideline (Version 9.1, October 2018) (http://www.eacsociety.org/guidelines/eacsguidelines/eacs-guidelines.html)
  6. Principles and practice of Infectious Disease. Mandell, Douglas, and Bennett’s 8th edition, 1548-49, 2015.
  7. Chu C and Selwyn PA. Diagnosis and initial management of acute HIV infection. Am Fam Physician. 81: 1239-44, 2010.
  8. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-70, 1996.
  9. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 373: 795-807, 2015.
  10. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 373: 808-22, 2015.
  11. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 375: 830-9, 2016.
  12. HIV薬剤耐性検査ガイドラインver, 10 (平成28年度日本医療研究開発機構エイズ対策実用化研究事業「国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究」班) (https://www.hiv-resistance.jp/resistance04.htm)
  13. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 379: 979-81, 2018.
  14. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 340: 1683-4, 1999.
  15. Lori F. and Lisziewick J. Structured Treatment Interruption for the Management of HIV Infection. JAMA 286: 2981-7, 2001.
  16. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 194: 725-33, 2006.
  17. SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 368: 207-17, 2013.
  18. Stöhr W, Fidler S, McClure M, et al. Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy. PLoS One. 8: e78287, 2013.